https://www.selleckchem.com/pr....oducts/elimusertib-b
improvement in quality of life, implying that the full benefits of onabotulinumtoxinA are not captured by headache day reduction. ClinicalTrials.gov identifiers, NCT00156910 (PREEMPT 1) and NCT00168428 (PREEMPT 2). ClinicalTrials.gov identifiers, NCT00156910 (PREEMPT 1) and NCT00168428 (PREEMPT 2). The clinical and immunological profile of patients with dipeptidyl peptidase-4 inhibitor (DPP4i)-associated bullous pemphigoid (BP) is inconsistent in the current literature. The aims were to investigate the clinical and immu
Like
Comment
Share
